Literature DB >> 11296976

Rating of arthritis health states by patients, physicians, and the general public. Implications for cost-utility analyses.

M E Suarez-Almazor1, B Conner-Spady.   

Abstract

We elicited preferences for 2 arthritis health states (mild and severe) using visual analog scales, time tradeoff, and standard gamble by interviewing 104 individuals from the general public, 51 patients with rheumatoid arthritis, and 43 health professionals. The health scenarios were based on attributes described in a health status classification instrument, the EuroQol (EQ-5D). In addition, we compared the ratings in our survey with those obtained for the same scenarios by one of the scoring algorithms used for the EQ-5D (York weights). Statistically significant differences were observed in the ratings of the health scenarios, mostly for the severe vignette. Most of the variability was related to the method employed. The cost-utility ratio for a hypothetical intervention varied according to the method employed to determine the utility of the health states, from $15,000 to $111,000 US per quality adjusted life year (QALY). Patient derived weights resulted in cost-utility ratios that ranged from $39,000 to $222,000. Our findings show that the methodology used to elicit and analyze utilities can have substantial implications in the economic evaluation of interventions for patients with RA.

Entities:  

Mesh:

Year:  2001        PMID: 11296976

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  14 in total

1.  Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer.

Authors:  K Lien; V C Tam; Y J Ko; N Mittmann; M C Cheung; K K W Chan
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

2.  How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?

Authors:  Annelies Boonen; Désirée van der Heijde; Robert Landewé; Astrid van Tubergen; Herman Mielants; Maxime Dougados; Sjef van der Linden
Journal:  Ann Rheum Dis       Date:  2007-01-09       Impact factor: 19.103

3.  Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.

Authors:  Anthony Russell; Ariel Beresniak; Louis Bessette; Boulos Haraoui; Proton Rahman; Carter Thorne; Ross Maclean; Danielle Dupont
Journal:  Clin Rheumatol       Date:  2008-12-17       Impact factor: 2.980

4.  Differences in EQ-5D-3L health state valuations among patients with musculoskeletal diseases, health care professionals and healthy volunteers.

Authors:  Anja Schwalm; You-Shan Feng; Jörn Moock; Thomas Kohlmann
Journal:  Eur J Health Econ       Date:  2014-10-05

5.  Does diabetes have an impact on health-state utility? a study of Asians in Singapore.

Authors:  P Wang; E S Tai; J Thumboo; Hubertus J M Vrijhoef; Nan Luo
Journal:  Patient       Date:  2014       Impact factor: 3.883

6.  Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases.

Authors:  Myoung-Hee Kim; Young-Shin Cho; Wan-Sik Uhm; Sehyun Kim; Sang-Cheol Bae
Journal:  Qual Life Res       Date:  2005-06       Impact factor: 4.147

7.  Variations in Physician Attitudes Regarding ADHD and Their Association With Prescribing Practices.

Authors:  R Christopher Sheldrick; Laurel K Leslie; Angie Mae Rodday; Susan K Parsons; Tully S Saunders; John B Wong
Journal:  J Atten Disord       Date:  2012-11-09       Impact factor: 3.256

Review 8.  An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.

Authors:  Nick J Bansback; Dean A Regier; Roberta Ara; Alan Brennan; Kamran Shojania; John M Esdaile; Aslam H Anis; Carlo A Marra
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 9.  The humanistic and economic burden of systemic lupus erythematosus : a systematic review.

Authors:  Rachel Meacock; Nicola Dale; Mark J Harrison
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

10.  Cost-effectiveness of systemic therapies for metastatic pancreatic cancer.

Authors:  V C Tam; Y J Ko; N Mittmann; M C Cheung; K Kumar; S Hassan; K K W Chan
Journal:  Curr Oncol       Date:  2013-04       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.